Abstract:As a prototypical member of the IL-17 family, interleukin-17A (IL-17A) has received increasing attentions for its potent proinflammatory role as well as potential to be a key therapeutic target in human autoimmune inflammatory diseases; however, its roles in other pathological scenarios like neuroinflammations are not fully elucidated yet but appear essentially correlating and promising. Glaucoma is the leading cause of irreversible blindness with complicated pathogenesis still to be understood, where neuroinflammation was reported to be critically involved in its both initiation and progression. Whether IL-17A takes part in the pathogenesis of glaucoma through interfering neuroinflammation due to its potent proinflammatory effect is still unknown. In the present study, we investigated the role of IL-17A in the pathological process of glaucoma neuropathy as well as its relationship with the predominant immune inflammation mediator microglia in retina, trying to elucidate the underlying mechanisms from the view of inflammation modulation. In our study, RNA sequencing was performed for the retinas of chronic ocular hypertension (COH) and control mice. Western blot, RT-PCR, immunofluorescence, and ELISA were used to evaluate the microglial activation and proinflammatory cytokines release at conditioned levels of IL-17A, along with assessment of optic nerve integrity including retinal ganglion cells (RGCs) counting, axonal neurofilament quantification, and flash visual-evoked potential (F-VEP) examination. And the possibly involved signaling pathways were screened out to go through further validation in scenarios with conditioned IL-17A. Subsequently, IL-17A was found to be significantly upregulated in COH retina. Furthermore, suppression of IL-17A effectively diminished the loss of RGCs, improved axonal quality, and F-VEP performance in COH mice. Mechanistically, IL-17A promoted microglial activation and proinflammatory cytokines release along with enhanced phenotypic conversion of activated microglia to M2-type in early stage and to M1-type in late stage in glaucomatous retinas. Microglia elimination decreased the proinflammatory factors secretion, enhanced the RGCs survival and axonal quality mediated by IL-17A. Furthermore, IL-17A-induced the overactivation of microglia in glaucomatous condition was alleviated after blocking the p38 MAPK pathway. Taken together, IL-17A is involved in the regulation of retinal immune response and RGCs cell death in experimental glaucoma by essentially promoting retinal microglial activation via p38 MAPK signaling pathway. IL-17A dynamically regulates the phenotypic conversion of retinal microglia in experimental glaucoma partly depending on the duration of elevated intraocular pressure. Suppression of IL-17A contributes to alleviate glaucoma neuropathy and exhibits promising potential as an innovative target for therapeutic strategy in glaucoma.

TRPV4-induced Müller cell gliosis and TNF-α elevation-mediated retinal ganglion cell apoptosis in glaucomatous rats via JAK2/STAT3/NF-κB pathway

TRPV4 antagonist suppresses retinal ganglion cell apoptosis by regulating the activation of CaMKII and TNF-α expression in a chronic ocular hypertension rat model

Soluble tumor necrosis factor-alpha-induced hyperexcitability contributes to retinal ganglion cell apoptosis by enhancing Nav1.6 in experimental glaucoma

Modulation of TRPV4-mediated TNF-α expression in Müller glia and subsequent RGC apoptosis by statins

In glaucoma the upregulated truncated TrkC.T1 receptor isoform in glia causes increased TNF-alpha production, leading to retinal ganglion cell death.

Müller cells under hydrostatic pressure modulate retinal cell survival via TRPV1/PLCγ1 complex‐mediated calcium influx in experimental glaucoma

The Effect of A2AReceptor Antagonist on Microglial Activation in Experimental Glaucoma

EphrinB/EphB Forward Signaling in Müller Cells Causes Apoptosis of Retinal Ganglion Cells by Increasing Tumor Necrosis Factor Alpha Production in Rat Experimental Glaucomatous Model

Interplay between Müller cells and microglia aggravates retinal inflammatory response in experimental glaucoma

Th1 cells contribute to retinal ganglion cell loss in glaucoma in a VCAM-1-dependent manner

Expression of TNF-α and TNF-R1 in Retinal Glial Cells of a Rat Chronic Elevated Intraocular Pressure Model

CTRP 9 mitigates the apoptosis and unfolded protein response of OGD/R-induced retinal ganglion cells by regulating the AMPK pathway

Aryl hydrocarbon receptor dependent anti-inflammation and neuroprotective effects of tryptophan metabolites on retinal ischemia/reperfusion injury

Protective effects of triptolide on retinal ganglion cells in a rat model of chronic glaucoma.

Inhibition of TLR4 alleviates the inflammation and apoptosis of retinal ganglion cells in high glucose

Neurodegenerative and inflammatory pathway components linked to TNF-α/TNFR1 signaling in the glaucomatous human retina

Regulatory mechanisms of retinal ganglion cell death in normal tension glaucoma and potential therapies

Interleukin-17A Modulates Retinal Inflammation by Regulating Microglial Activation Via the P38 MAPK Pathway in Experimental Glaucoma Neuropathy

The Roles of Transient Receptor Potential Ion Channels in Pathologies of Glaucoma

Therapeutic Retrobulbar Inhibition of STAT3 Protects Ischemic Retina Ganglion Cells

Activation of Autophagy and Paraptosis in Retinal Ganglion Cells after Retinal Ischemia and Reperfusion Injury in Rats